Management of Stable Severe Hyperkalaemia
For a stable patient with severe hyperkalaemia (K+ >6.0 mEq/L), initiate immediate treatment with IV calcium for cardiac membrane stabilization, followed by combination therapy with insulin-glucose AND nebulized salbutamol to shift potassium intracellularly, then promote potassium elimination with loop diuretics (if non-oliguric) and consider potassium binders, while monitoring ECG and repeat potassium levels within hours. 1, 2
Immediate Stabilization (First 5 Minutes)
Even in stable patients with severe hyperkalaemia, cardiac membrane stabilization is the priority:
The 2018 European Society of Cardiology consensus emphasizes that patients with chronic kidney disease, diabetes, or heart failure often tolerate K+ levels up to 6 mEq/L without arrhythmias, but this is unpredictable and should not delay treatment in severe cases 3.
Shift Potassium Intracellularly (Within 15-30 Minutes)
Use combination therapy for maximum effect 1, 2, 4:
Insulin-glucose: 10 units regular insulin with 25-50g glucose (50 mL of D50) IV over 15-30 minutes 1, 2
- Onset: 30-60 minutes
- Duration: 4-6 hours
- Monitor glucose closely—hypoglycemia risk is substantial, especially in non-diabetics 5
Sodium bicarbonate: 50 mEq IV over 5 minutes 1
Important pitfall: These shifting agents are temporary (lasting 1-4 hours) and do NOT eliminate potassium from the body—rebound hyperkalaemia can occur after 2 hours 3. Therefore, potassium elimination strategies must be initiated simultaneously.
Eliminate Potassium from the Body (Ongoing)
For Non-Oliguric Patients:
- Furosemide 40-80 mg IV 1, 2
- Effectiveness depends on residual kidney function 2
- Consider higher doses in patients with chronic kidney disease
Potassium Binders:
The 2021 Mayo Clinic guidelines recommend considering newer potassium binders over older agents 2:
Sodium zirconium cyclosilicate (SZC) or patiromer are preferred 2
Avoid sodium polystyrene sulfonate (Kayexalate) in acute settings 5
For Oliguric or End-Stage Renal Disease:
Monitoring Protocol
Repeat potassium levels within 1-2 hours after initial treatment 2:
- Assess for rebound hyperkalaemia (common after 2 hours) 3
- Continuous ECG monitoring until K+ <6.0 mEq/L 1, 2
- Monitor glucose levels closely for hypoglycemia 5
Critical Medication Review
Do NOT discontinue RAAS inhibitors reflexively 2, 3, 10:
- The 2018 ESC consensus and 2021 Mayo guidelines emphasize that RAASi therapy reduces mortality and morbidity 3, 2, 3
- Discontinuation is associated with increased mortality, heart failure hospitalizations, and progression to end-stage kidney disease 10
- Only reduce/discontinue RAASi if K+ >6.5 mEq/L AND other measures have failed 2
Review and stop contributing medications 3:
- NSAIDs
- Potassium supplements
- Potassium-sparing diuretics (if not essential)
- Trimethoprim-sulfamethoxazole
- Salt substitutes
Key Pitfalls to Avoid
- Waiting for ECG changes: Severe hyperkalaemia requires treatment even without ECG abnormalities 3
- Using shifting agents alone: Always combine with elimination strategies to prevent rebound 3
- Premature RAASi discontinuation: Manage hyperkalaemia through other means first 2, 3, 10
- Relying on old potassium binders: SPS is ineffective acutely and potentially harmful 2, 5
- Forgetting glucose monitoring: Hypoglycemia after insulin-glucose is common and dangerous 5
Long-Term Prevention
Once stabilized, the 2026 ESC guidelines recommend 9:
- Correct metabolic acidosis
- Optimize glycemic control in diabetics
- Consider modern potassium binders (patiromer, SZC) for recurrent hyperkalaemia 2, 9
- Maintain RAASi therapy at maximum tolerated doses with potassium binder support 2, 10
- Potassium-restricted diet
- Regular monitoring (within 1 week after any medication changes) 2